IL278122B2 - Pteridinone compounds and uses thereof - Google Patents
Pteridinone compounds and uses thereofInfo
- Publication number
- IL278122B2 IL278122B2 IL278122A IL27812220A IL278122B2 IL 278122 B2 IL278122 B2 IL 278122B2 IL 278122 A IL278122 A IL 278122A IL 27812220 A IL27812220 A IL 27812220A IL 278122 B2 IL278122 B2 IL 278122B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- nitrogen
- ring
- sulfur
- oxygen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661744P | 2018-04-24 | 2018-04-24 | |
| PCT/US2019/028604 WO2019209757A1 (en) | 2018-04-24 | 2019-04-23 | Pteridinone compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278122A IL278122A (en) | 2020-11-30 |
| IL278122B1 IL278122B1 (en) | 2023-09-01 |
| IL278122B2 true IL278122B2 (en) | 2024-01-01 |
Family
ID=66655428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278122A IL278122B2 (en) | 2018-04-24 | 2019-04-23 | Pteridinone compounds and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11059826B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3784669B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7479293B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112218865B (cg-RX-API-DMAC7.html) |
| AR (1) | AR114828A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019257651B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3097774A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2969982T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL278122B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI884914B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019209757A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3784669B1 (en) | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| US12617784B2 (en) | 2019-01-29 | 2026-05-05 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT inhibitor |
| AU2020368368B2 (en) * | 2019-10-14 | 2026-03-19 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
| WO2022023339A1 (en) | 2020-07-29 | 2022-02-03 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
| EP4238974A4 (en) * | 2020-10-28 | 2024-10-23 | Adlai Nortye Biopharma Co., Ltd. | HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND |
| TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
| TW202333697A (zh) * | 2022-01-30 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Wnt通路抑制劑化合物 |
| CN114436918B (zh) * | 2022-02-23 | 2023-05-23 | 郑州大学 | 环丁-1-烯胺类化合物及其制备方法和在药物中的应用 |
| WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| US20240217951A1 (en) * | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020722A1 (de) * | 2001-09-04 | 2003-03-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| WO2005123736A1 (de) * | 2004-06-21 | 2005-12-29 | Boehringer Ingelheim International Gmbh | Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| WO2006018182A1 (en) * | 2004-08-14 | 2006-02-23 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| WO2006021378A1 (de) * | 2004-08-25 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| US20130225593A1 (en) * | 2012-02-23 | 2013-08-29 | Boehringer Ingelheim International Gmbh | Dihydropteridinones ii |
| WO2014127815A1 (en) * | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim International Gmbh | Dihydropteridinones i |
| WO2014127816A1 (en) * | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim International Gmbh | Dihydropteridinones ii |
| WO2015193229A1 (de) * | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe |
| CN105801582A (zh) * | 2016-04-12 | 2016-07-27 | 合肥工业大学 | 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| AU2011226830A1 (en) * | 2004-08-14 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007014838A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20160111520A (ko) | 2014-01-31 | 2016-09-26 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| CA2986441A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP3784669B1 (en) * | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
-
2019
- 2019-04-23 EP EP19726791.7A patent/EP3784669B1/en active Active
- 2019-04-23 JP JP2020559365A patent/JP7479293B2/ja active Active
- 2019-04-23 WO PCT/US2019/028604 patent/WO2019209757A1/en not_active Ceased
- 2019-04-23 AU AU2019257651A patent/AU2019257651B2/en active Active
- 2019-04-23 AR ARP190101061A patent/AR114828A1/es unknown
- 2019-04-23 ES ES19726791T patent/ES2969982T3/es active Active
- 2019-04-23 CN CN201980035546.1A patent/CN112218865B/zh active Active
- 2019-04-23 US US16/391,407 patent/US11059826B2/en active Active
- 2019-04-23 CA CA3097774A patent/CA3097774A1/en active Pending
- 2019-04-23 TW TW108114117A patent/TWI884914B/zh active
- 2019-04-23 IL IL278122A patent/IL278122B2/en unknown
-
2021
- 2021-03-01 US US17/188,132 patent/US11572364B2/en active Active
-
2022
- 2022-12-05 US US18/075,270 patent/US12384790B2/en active Active
-
2023
- 2023-06-15 JP JP2023098522A patent/JP2023116712A/ja active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020722A1 (de) * | 2001-09-04 | 2003-03-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| WO2005123736A1 (de) * | 2004-06-21 | 2005-12-29 | Boehringer Ingelheim International Gmbh | Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| WO2006018182A1 (en) * | 2004-08-14 | 2006-02-23 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| WO2006021378A1 (de) * | 2004-08-25 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| US20130225593A1 (en) * | 2012-02-23 | 2013-08-29 | Boehringer Ingelheim International Gmbh | Dihydropteridinones ii |
| WO2014127815A1 (en) * | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim International Gmbh | Dihydropteridinones i |
| WO2014127816A1 (en) * | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim International Gmbh | Dihydropteridinones ii |
| WO2015193229A1 (de) * | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe |
| CN105801582A (zh) * | 2016-04-12 | 2016-07-27 | 合肥工业大学 | 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途 |
Non-Patent Citations (2)
| Title |
|---|
| LI QIU ET AL,, DESIGN, SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY OF NOVEL SUBSTITUTED 2-AMINO-7,8-DIHYDROPTERIDIN-6(5H)-ONE DERIVATIVES, 29 July 2017 (2017-07-29) * |
| LUKE W. KOBLAN ET AL,, ASSESSMENT OF BROMODOMAIN TARGET ENGAGEMENT BY A SERIES OF BI2536 ANALOGUES WITH MINIATURIZED BET-BRET, 6 December 2016 (2016-12-06) * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202010744A (zh) | 2020-03-16 |
| JP7479293B2 (ja) | 2024-05-08 |
| EP3784669A1 (en) | 2021-03-03 |
| CN112218865B (zh) | 2024-03-12 |
| TWI884914B (zh) | 2025-06-01 |
| US20230312587A1 (en) | 2023-10-05 |
| IL278122B1 (en) | 2023-09-01 |
| US12384790B2 (en) | 2025-08-12 |
| US11059826B2 (en) | 2021-07-13 |
| CN112218865A (zh) | 2021-01-12 |
| US20220363685A1 (en) | 2022-11-17 |
| IL278122A (en) | 2020-11-30 |
| AU2019257651A1 (en) | 2020-10-15 |
| WO2019209757A1 (en) | 2019-10-31 |
| AR114828A1 (es) | 2020-10-21 |
| US11572364B2 (en) | 2023-02-07 |
| JP2021522237A (ja) | 2021-08-30 |
| EP3784669B1 (en) | 2023-10-25 |
| ES2969982T3 (es) | 2024-05-23 |
| AU2019257651B2 (en) | 2023-05-25 |
| CA3097774A1 (en) | 2019-10-31 |
| JP2023116712A (ja) | 2023-08-22 |
| US20190322673A1 (en) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276147B2 (en) | Gcn2 inhibitors and uses thereof | |
| US11467490B2 (en) | Salt, acid generator, resist composition and method for producing resist pattern | |
| US6440975B1 (en) | Amino acid derivatives, the preparation and use thereof as endothelin antagonists | |
| US11739056B2 (en) | Carboxylate, carboxylic acid generator, resist composition and method for producing resist pattern | |
| US20230087041A1 (en) | Methods for treating neurological disorders | |
| US10597375B2 (en) | Halogen-substituted heterocyclic compound | |
| US6670367B1 (en) | Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists | |
| US20100278733A1 (en) | Composition for diagnosis of amyloid-related disease | |
| TWI901805B (zh) | 鹽、酸產生劑、抗蝕劑組成物及抗蝕劑圖案的製造方法 | |
| RU2007116725A (ru) | Диаминоалкановые ингибиторы аспарагиновой протеазы | |
| US20190119282A1 (en) | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway | |
| TW202229221A (zh) | 羧酸鹽、抗蝕劑組成物及抗蝕劑圖案的製造方法 | |
| WO2023051261A1 (zh) | 一种亚胺类化合物及其应用 | |
| US6448248B1 (en) | Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists | |
| CA2082617C (en) | Mesomorphic compound, liquid crystal composition, liquid crystal device, display apparatus and display method | |
| EP2113258A1 (en) | Aurone derivative-containing composition for diagnosis | |
| EP4238960A1 (en) | Amide derivative having antiviral activity | |
| US5604178A (en) | N-(substituted amino)pyrrole derivatives, and herbicidal compositions | |
| CN1261352A (zh) | 新的β-氨基和β-叠氮基羧酸衍生物、其制备及其作为内皮素受体拮抗剂的应用 | |
| US6358983B1 (en) | Heterocyclically substituted α-hydroxycarboxylic acid derivatives, method for producing the same and their use as endothelin receptor antagonists | |
| US5683964A (en) | N-(substituted amino)imide derivatives, preparation process thereof, and herbicidal composition | |
| KR930011304B1 (ko) | 피리다지논 유도체와 그의 제조방법 | |
| HK40101424A (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| HK1026417A (en) | Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists | |
| HK1227944A1 (en) | Compounds for use in treating alzheimer’s disease in apoe4+/+ patients |